Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 105-112.e1 , March 2010

Safety of extended-release niacin/laropiprant in patients with dyslipidemia

  • James McKenney, PharmD

      Affiliations

    • National Clinical Research Inc., 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Harold Bays, MD

      Affiliations

    • Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    • ,
  • Michael Koren, MD, FACC

      Affiliations

    • Jacksonville Center for Clinical Research, Jacksonville, FL, USA
    • ,
  • Christie M. Ballantyne, MD

      Affiliations

    • Methodist DeBakey Heart and Vascular Center and Baylor College of Medicine, Houston, TX, USA
    • ,
  • John F. Paolini, MD, PhD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ, USA
    • ,
  • Yale Mitchel, MD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ, USA
    • ,
  • Abigaile Betteridge, BS

      Affiliations

    • Merck Research Laboratories, Rahway, NJ, USA
    • ,
  • Olga Kuznetsova, PhD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ, USA
    • ,
  • Aditi Sapre, PhD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ, USA
    • ,
  • Christine McCrary Sisk, BS

      Affiliations

    • Merck Research Laboratories, Rahway, NJ, USA
    • ,
  • Darbie Maccubbin, PhD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ, USA

Received 6 January 2010 ,Accepted 7 February 2010.

References 

  1. Gotto AM. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002;144(6 Suppl):S33–S42
  2. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins—an idea whose time for testing is coming, Part I. Circulation. 2001;104:2376–2383
  3. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report. Circulation. 2002;106:3143–3421
  4. Anon . The coronary drug project. JAMA. 1972;221:918
  5. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  6. Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ. Types of change in coronary stenosis severity and their relative importance in overall progression and regression in coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment study. Ann NY Acad Sci. 1995;748:407–417
  7. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, 3-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80:111–115
  8. The Coronary Drug Project Research Group . Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–381
  9. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  10. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99:22C–31C
  11. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642–650
  12. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med. 2004;62:229–234
  13. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med. 1994;154:1586–1595
  14. Mills E, Prousky J, Raskin G, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol. 2003;3:4–11
  15. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol. 2007;99:530–534
  16. Kamal-Bahl , Burke T, Watson D. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin. 2008;24:1817–1821
  17. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103:6682–6687
  18. Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol. 1979;57:114–117
  19. Negishi M, Sugimoto Y, Ichikawa A. Prostanoid receptors and their biological actions. Prog Lipid Res. 1993;32:417–434
  20. Sturino CF, O'Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid (MK-0524). J Med Chem. 2007;50:794–806
  21. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesteroaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62:1959–1970
  22. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101:625–630
  23. Van Hecken A, Depré M, De Lepeleire I, et al. The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers. Eur J Pharmacol. 2007;63:135–141
  24. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharacol Ther. 2008;83:840–847
  25. Gleim G, Ballantyne CM, Liu N, et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol. 2009;16:90–97
  26. Koren MJ, Maccubbin D, Davidson M, et al. Flushing profile of extended release niacin/laropiprant versus gradually titrated Niaspan™ in patients with dyslipidemia. [abstract] J Am Coll Cardiol. 2008;51(Suppl 1):A324
  27. Tatò F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction of serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol. 1998;81:805–807
  28. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med. 1992;92:77–81
  29. Grundy SM, Vega GL, McGovern ME, et al. Diabetes Multicenter Research Group Efficacy, safety, and tolerability of once-daily niacin for the treatment of dysplipidemia associated with type 2 diabetes—results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162:1568–1576
  30. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA. 2000;284:1263–1270
  31. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47:1097–1104

PII: S1933-2874(10)00049-8

doi: 10.1016/j.jacl.2010.02.002

Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 105-112.e1 , March 2010

Article Tools

* Image Usage & Resolution